Vesalius Biocapital III Fund closes at €120 million

The fund includes commitments of €30m from the European Investment Fund (EIF) and new and existing investors from Europe, the Americas and MENA. Vesalius Biocapital III has already executed three investments. These include investments in Forendo, a clinical stage drug development company focusing on novel treatments in women’s health; Mecuris, a Munich-based medtech developing an easy-to-use online platform for customizable and 3D-printed orthotics and prosthetics; and SWORD Health, a tech-enabled provider of physical therapy, pairing its AI-powered digital therapists with human clinical teams to recover patients faster and better.

Vesalius Biocapital III targets later-stage European life science companies in drug development, medtech, diagnostics and digital health with the goal of investing in 10 to 15 companies over the lifetime of the fund.